8-K: P3 Health Partners Reports 26% Revenue Increase but Faces Profitability Challenges in Q3 2024

P3 Health Partners announced a 26% year-over-year revenue increase to $362.1 million for the third quarter of 2024, but experienced significant losses due to lower risk adjustments and higher medical expenses.

Summary

• P3 Health Partners reported a 26% increase in revenue to $362.1 million for the third quarter of 2024, compared to $288.4 million in the same period last year.
• Capitated revenue also saw a 25% increase, reaching $357.7 million.
• However, the company experienced a gross loss of $39.8 million, a significant downturn from a $9.1 million gross profit in the prior year.
• Medical margin was $0.5 million, a sharp decrease from $36.2 million in the prior year.
• The net loss for the quarter was $102.9 million, compared to a $37.3 million loss in the third quarter of 2023.
• Adjusted EBITDA loss was $71.0 million, compared to a $22.3 million loss in the same quarter of the previous year.
• The company has withdrawn its previous financial guidance for the fiscal year ending December 31, 2024, due to lower-than-expected risk adjustments and elevated medical costs.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to significant losses, decreased profitability, and the withdrawal of financial guidance. While revenue growth is positive, the overall financial health of the company is concerning.

Positives

• The company achieved a 26% year-over-year increase in total revenue, reaching $362.1 million.
• Capitated revenue also grew significantly, increasing by 25% to $357.7 million.
• P3 Health Partners has identified more than $130 million of potential improvement opportunities.

Negatives

• The company reported a gross loss of $39.8 million, a significant decrease from the $9.1 million gross profit in the same quarter of the previous year.
• Medical margin decreased dramatically to $0.5 million from $36.2 million year-over-year.
• The net loss for the quarter was $102.9 million, a substantial increase from the $37.3 million loss in the prior year.
• Adjusted EBITDA loss worsened to $71.0 million, compared to a $22.3 million loss in the third quarter of 2023.
• The company withdrew its previous financial guidance for the fiscal year ending December 31, 2024.

Risks

• The company is facing challenges due to lower-than-expected risk adjustments.
• Elevated medical costs are negatively impacting profitability.
• There is a risk that the company may not achieve its identified improvement opportunities.
• The withdrawal of financial guidance creates uncertainty about the company's future performance.
• The company's ability to maintain compliance with debt covenants is a potential risk.

Future Outlook

The company has withdrawn its previous guidance for fiscal year ending December 31, 2024, and investors should no longer rely on it. Management believes P3 will be well-positioned to unlock value and generate sustainable, profitable growth in the medium and long term.

Management Comments

• Aric Coffman, CEO of P3, stated, 'As we execute on our strategic initiatives, we believe P3 will be well-positioned to unlock the value built within our platform and generate sustainable, profitable growth in the medium and long term.'
• Aric Coffman also noted, 'We have identified more than $130 million of potential improvement opportunities, and while near-term dynamics have negatively affected our financial results, demand for our platform has never been stronger as we continue to deliver value to patients, payors and our PCP partners.'

Industry Context

The healthcare industry is facing increasing pressure on profitability due to rising medical costs and changes in risk adjustment models. P3 Health Partners' results reflect these broader industry challenges, particularly in the value-based care sector. Competitors in the population health management space are likely facing similar headwinds.

Comparison to Industry Standards

• P3 Health Partners' significant drop in medical margin from $115 PMPM to $1 PMPM is a concerning deviation from industry norms, where medical margins are typically a key indicator of profitability for value-based care providers.
• Companies like Oak Street Health and Cano Health, which also operate in the value-based care space, have been under pressure to demonstrate profitability, but P3's results indicate a more severe challenge in managing medical expenses.
• While revenue growth is positive, the inability to control medical costs and achieve a positive gross profit is a major concern compared to industry benchmarks.
• The withdrawal of financial guidance is also a negative signal, as most public companies in the healthcare sector strive to provide reliable forecasts to investors.

Stakeholder Impact

• Shareholders will be negatively impacted by the significant losses and the withdrawal of financial guidance.
• Employees may be concerned about the company's financial stability and potential restructuring.
• Customers (patients and payors) may be concerned about the company's ability to provide consistent services.
• Suppliers and creditors may be concerned about the company's ability to meet its financial obligations.

Next Steps

• Management will host a conference call and webcast on November 12, 2024, at 4:30 PM ET to discuss the results.
• The company will focus on executing key 2025 initiatives with a focus on improvements in profitability metrics.

Key Dates

Keywords

P3 Health Partners, Financial Results, Q3 2024, Revenue, Capitated Revenue, Gross Loss, Medical Margin, Net Loss, Adjusted EBITDA, Risk Adjustment, Medical Expenses, Healthcare, Population Health Management